Efficacy of BRAF-Inhibitor Therapy in BRAF V600E-Mutated Adult Langerhans Cell Histiocytosis
Abstract
Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm. To date, there is a lack of U.S. Food and Drug Administration–approved treatments in adult LCH to establish optimal first-line therapy. We conducted a retrospective, single-center case series evaluating the use of BRAF inhibitors in adult patients with BRAFV600E- LCH proven by biopsy. Our case series is the first to report the use of BRAF inhibitors as first-line therapy in...
Paper Details
Title
Efficacy of BRAF-Inhibitor Therapy in BRAF V600E-Mutated Adult Langerhans Cell Histiocytosis
Published Date
Oct 12, 2020
Journal
Volume
25
Issue
12
Pages
1001 - 1004
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History